WO2022160377A1 - 一种新型冠状病毒中和抗体检测试纸 - Google Patents
一种新型冠状病毒中和抗体检测试纸 Download PDFInfo
- Publication number
- WO2022160377A1 WO2022160377A1 PCT/CN2021/075736 CN2021075736W WO2022160377A1 WO 2022160377 A1 WO2022160377 A1 WO 2022160377A1 CN 2021075736 W CN2021075736 W CN 2021075736W WO 2022160377 A1 WO2022160377 A1 WO 2022160377A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antibody
- detection
- test paper
- colloidal gold
- novel coronavirus
- Prior art date
Links
- 238000012360 testing method Methods 0.000 title claims abstract description 160
- 241000711573 Coronaviridae Species 0.000 title claims abstract description 128
- 230000003472 neutralizing effect Effects 0.000 title claims abstract description 89
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims abstract description 75
- 238000003908 quality control method Methods 0.000 claims abstract description 37
- 238000001179 sorption measurement Methods 0.000 claims abstract description 27
- 239000000427 antigen Substances 0.000 claims abstract description 21
- 102000036639 antigens Human genes 0.000 claims abstract description 21
- 108091007433 antigens Proteins 0.000 claims abstract description 21
- 238000000034 method Methods 0.000 claims abstract description 18
- 239000000758 substrate Substances 0.000 claims abstract description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 17
- 238000011068 loading method Methods 0.000 claims abstract description 10
- 102100035765 Angiotensin-converting enzyme 2 Human genes 0.000 claims abstract description 9
- 108090000975 Angiotensin-converting enzyme 2 Proteins 0.000 claims abstract description 9
- 238000010521 absorption reaction Methods 0.000 claims abstract description 8
- 238000001514 detection method Methods 0.000 claims description 170
- SWGJCIMEBVHMTA-UHFFFAOYSA-K trisodium;6-oxido-4-sulfo-5-[(4-sulfonatonaphthalen-1-yl)diazenyl]naphthalene-2-sulfonate Chemical compound [Na+].[Na+].[Na+].C1=CC=C2C(N=NC3=C4C(=CC(=CC4=CC=C3O)S([O-])(=O)=O)S([O-])(=O)=O)=CC=C(S([O-])(=O)=O)C2=C1 SWGJCIMEBVHMTA-UHFFFAOYSA-K 0.000 claims description 33
- 239000000243 solution Substances 0.000 claims description 24
- 238000011161 development Methods 0.000 claims description 22
- 238000002360 preparation method Methods 0.000 claims description 17
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 12
- 102000005962 receptors Human genes 0.000 claims description 11
- 108020003175 receptors Proteins 0.000 claims description 11
- 241000283707 Capra Species 0.000 claims description 10
- 102100031673 Corneodesmosin Human genes 0.000 claims description 10
- 101710139375 Corneodesmosin Proteins 0.000 claims description 10
- 239000011248 coating agent Substances 0.000 claims description 10
- 238000000576 coating method Methods 0.000 claims description 10
- 239000003085 diluting agent Substances 0.000 claims description 5
- 238000002372 labelling Methods 0.000 claims description 5
- 238000010790 dilution Methods 0.000 claims description 4
- 239000012895 dilution Substances 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 239000002250 absorbent Substances 0.000 claims description 3
- 230000002745 absorbent Effects 0.000 claims description 3
- 238000003745 diagnosis Methods 0.000 claims description 3
- 239000013642 negative control Substances 0.000 claims description 3
- 230000035945 sensitivity Effects 0.000 abstract description 5
- 238000003756 stirring Methods 0.000 description 14
- 239000012528 membrane Substances 0.000 description 11
- 238000002791 soaking Methods 0.000 description 5
- 229960005486 vaccine Drugs 0.000 description 5
- 241001678559 COVID-19 virus Species 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 230000002335 preservative effect Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 239000008213 purified water Substances 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 239000000020 Nitrocellulose Substances 0.000 description 3
- 229940098773 bovine serum albumin Drugs 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000011888 foil Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 229920001220 nitrocellulos Polymers 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 238000007789 sealing Methods 0.000 description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 239000012154 double-distilled water Substances 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 229940127121 immunoconjugate Drugs 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 2
- 229940038773 trisodium citrate Drugs 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 101710184444 Complexin Proteins 0.000 description 1
- 208000001528 Coronaviridae Infections Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 208000035415 Reinfection Diseases 0.000 description 1
- 108091005634 SARS-CoV-2 receptor-binding domains Proteins 0.000 description 1
- 101000629318 Severe acute respiratory syndrome coronavirus 2 Spike glycoprotein Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940125644 antibody drug Drugs 0.000 description 1
- 238000009175 antibody therapy Methods 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000006957 competitive inhibition Effects 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000002906 medical waste Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 208000026425 severe pneumonia Diseases 0.000 description 1
- 239000012475 sodium chloride buffer Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 125000000185 sucrose group Chemical group 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical group [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 229940074410 trehalose Drugs 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
- G01N33/6857—Antibody fragments
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/558—Immunoassay; Biospecific binding assay; Materials therefor using diffusion or migration of antigen or antibody
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/165—Coronaviridae, e.g. avian infectious bronchitis virus
Definitions
- the invention relates to the field of biomedical detection, in particular to a novel coronavirus neutralizing antibody detection test paper, a kit, a detection method and application.
- Antibody is a protein with immune effect produced by B lymphocytes stimulated by antigens in the human body, and mainly exists in blood and tissues. Antibodies have a Y-shaped structure, which helps them capture antigens precisely. After the microorganism invades the human body, it stimulates the body to produce a variety of antibodies, of which only some of the antibodies can recognize the microorganism and capture it before it invades the cells to protect the human body from infection. This process is called neutralization, and the antibodies that do the work are neutralizing antibodies. In the fight against the new coronavirus, neutralizing antibody therapy is to artificially supply antibodies to support the immune system to prevent the new coronavirus infection.
- the first is serum therapy, that is, after people are infected with the new coronavirus, they will produce an IgG antibody, which is a neutralizing antibody. This is the reason why the serum of recovered patients with new coronary pneumonia is used to treat other severe pneumonia patients. This method is the fastest to apply, but there are certain risks.
- the second is monoclonal antibody, which is an antibody that has been artificially screened and prepared, with a single component and strong specificity, also known as "biological missile". Monoclonal antibodies can accurately identify a certain antigenic site of the new coronavirus, resulting in a highly effective antiviral effect.
- the last one is genetically engineered antibodies, which are modifications to the amino acid sequence of antibodies, which are more effective.
- neutralizing antibodies are designed to train the human immune system to master the method of eliminating the new coronavirus, and to effectively remove them when the virus invades, focusing on prevention.
- Neutralizing antibody drugs are mainly to kill the new coronavirus accurately and efficiently, with fast onset and considerable therapeutic effect.
- the detection of neutralizing antibodies can determine whether it is safer to return to work or participate in more social activities. At this stage, it is confirmed whether the recovered patients or asymptomatic infected persons are at risk of re-infection, and the vaccine will be successfully developed and widely used in the later stage. , which can be used as an evaluation index for vaccine efficacy.
- Existing detection methods for SARS-CoV-2 neutralizing antibodies mainly include enzyme-linked immunosorbent assay, chemiluminescence and other detection methods, and corresponding kits for these two methods are already on the market. However, the detection operation of the above method is relatively complicated and time-consuming, and the detection has low specificity and poor sensitivity, and the concentration level of the neutralizing antibody cannot be judged.
- the technical problem to be solved by the present invention is that the detection operation of the existing novel coronavirus neutralizing antibody is relatively complicated and time-consuming, and the specificity is low and the sensitivity is poor during detection, and the concentration level of the neutralizing antibody cannot be judged, thereby Provided are a new coronavirus neutralizing antibody detection test paper, a kit, and a detection method and application.
- a novel coronavirus neutralizing antibody detection test paper comprising: a substrate, and a sample loading pad, a colloidal gold adsorption pad, an antibody bearing film and a water absorption pad are sequentially overlapped and overlapped on the substrate; the antibody bearing film is provided with The detection line T1, the detection line T2 and the quality control line C are spaced apart, the detection line T2 is close to the colloidal gold adsorption pad, and the quality control line C is close to the water absorption pad;
- the colloidal gold adsorption pad is coated with the colloidal gold-labeled receptor binding domain RBD antigen of the new coronavirus S protein and the colloidal gold-labeled antibody unrelated to the new coronavirus;
- the detection line T1 is coated with the secondary antibody of the novel coronavirus antibody IgG;
- the detection line T2 is coated with angiotensin converting enzyme 2;
- the quality control line C is coated with a secondary antibody that specifically binds to an antibody unrelated to the colloidal gold-labeled novel coronavirus.
- the secondary antibody of the novel coronavirus antibody IgG is a mouse anti-human IgG monoclonal antibody
- the colloidal gold-labeled antibody unrelated to the new coronavirus is a rabbit IgG antibody; or
- the secondary antibody specifically bound to the colloidal gold-labeled novel coronavirus unrelated antibody is a goat anti-rabbit IgG polyclonal antibody.
- the present invention provides a method for preparing the novel coronavirus neutralizing antibody detection test paper, comprising the following steps:
- the detection line T1, the detection line T2 and the detection line T2 and quality control line C are connected to The detection line T1, the detection line T2 and the detection line T2 and quality control line C.
- the secondary antibody of the novel coronavirus antibody IgG is a mouse anti-human IgG monoclonal antibody
- the colloidal gold-labeled antibody unrelated to the new coronavirus is a rabbit IgG antibody; or
- the secondary antibody specifically bound to the colloidal gold-labeled novel coronavirus unrelated antibody is a goat anti-rabbit IgG polyclonal antibody.
- the coating concentration of the goat anti-rabbit IgG polyclonal antibody 2.0-2.5 mg/ml; or
- the coating concentration of the mouse anti-human IgG monoclonal antibody 0.5-0.6 mg/ml; or
- Angiotensin-converting enzyme 2 coating concentration 1.5-2.0 mg/ml; or
- Colloidal gold labeling concentration of the receptor binding domain RBD antigen of the novel coronavirus S protein 4-5 ⁇ g/ml; or
- Colloidal gold labeling concentration of rabbit IgG 4 ⁇ 5 ⁇ g/ml.
- the present invention provides a novel coronavirus neutralizing antibody detection device, including a housing, and the novel coronavirus neutralizing antibody detection test paper of the internal device or the novel coronavirus neutralizing antibody prepared by the preparation method. test paper;
- a sample hole is set at the corresponding sample pad, and an observation port is set at the detection line T2, the detection line T1 and the quality control line C.
- the present invention provides a novel coronavirus neutralizing antibody detection kit, comprising the novel coronavirus neutralizing antibody detection test paper, the novel coronavirus neutralizing antibody detection test paper prepared by the preparation method, or the novel coronavirus neutralizing antibody detection test paper. Coronavirus neutralizing antibody detection device.
- novel coronavirus neutralizing antibody detection test paper of the present invention the novel coronavirus neutralizing antibody detection test paper prepared by the preparation method, or the novel coronavirus neutralizing antibody detection device are used in the preparation and detection of the novel coronavirus neutralization Use of antibodies in products.
- the present invention provides a detection method for non-disease diagnosis of a novel coronavirus neutralizing antibody, using the novel coronavirus neutralizing antibody detection test paper, the novel coronavirus neutralizing antibody detection test paper prepared by the preparation method, or The novel coronavirus neutralizing antibody detection device.
- the sample is added to the sample loading pad of the detection test paper, and then the dilution solution is added on the sample loading pad, and the detection test paper is recorded as A test paper; at the same time, the dilution solution is added to another detection test paper to make a negative control.
- the test paper is recorded as the B test paper; after 15 minutes, the A test paper and the B test paper are observed, and the result is invalid after 20 minutes;
- test paper A when a purple-red band appears at the quality control line C and detection line T2 of test paper A, and there is no purple-red band at test line T1, the color development result of test paper A is consistent with the color development result of test paper B, and the test result is negative;
- the color development of the detection line T2 is deeper than that of the detection line T1, and the color development of the A test paper detection line T2 is higher than that of the B test paper detection line.
- the color of T2 is light, and the test results show that the sample contains a low titer of new coronavirus neutralizing antibodies;
- test paper A When test paper A has light purple-red stripes at the detection line T1 and detection line T2, the color depth of test line T1 and test line T2 is equal, and the color development of test line T2 of test paper A is lighter than that of test line T2 of test paper B.
- the results showed that the samples contained neutralizing antibody titers of the novel coronavirus;
- test paper When the A test paper has a purple-red band at the T1 test line, and no purple-red band appears at the T2 test line, the test result indicates that the sample contains a high titer of neutralizing antibodies to the new coronavirus;
- the quality control line C of the A test paper and the B test paper does not have a purple-red strip, it indicates an incorrect operation process or failure.
- the novel coronavirus neutralizing antibody detection test paper provided by the present invention, the substrate and on the substrate are successively overlapped with sample loading pads, colloidal gold adsorption pads, antibody carrying films and water absorbing pads; A detection line T1, a detection line T2 and a quality control line C are arranged at intervals, the detection line T2 is close to the colloidal gold adsorption pad, and the quality control line C is close to the water absorption pad; the colloidal gold adsorption pad is covered with The receptor binding domain RBD antigen of the new coronavirus S protein labeled with colloidal gold and the antibody unrelated to the new coronavirus labeled with colloidal gold; the detection line T1 is coated with the secondary antibody of the new coronavirus antibody IgG; the detection line T2 is coated with angiotensin-converting enzyme 2; the quality control line C is coated with a secondary antibody that specifically binds to an antibody unrelated to colloidal gold-labeled 2019-nCoV; in the above detection test paper, the colloidal gold
- the color development of the detection line T2 is deeper than that of the detection line T1, and the color development of the A test paper detection line T2 is higher than that of the B test paper detection line.
- the color of T2 is light, and the test results show that the sample contains a low titer of new coronavirus neutralizing antibodies;
- test paper A When test paper A has light purple-red stripes at the detection line T1 and detection line T2, the color depth of test line T1 and test line T2 is equal, and the color development of test line T2 of test paper A is lighter than that of test line T2 of test paper B.
- the results showed that the samples contained neutralizing antibody titers of the novel coronavirus;
- test paper When the A test paper has a purple-red band at the T1 test line, and no purple-red band appears at the T2 test line, the test result indicates that the sample contains a high titer of neutralizing antibodies to the new coronavirus;
- the quality control line C of the A test paper and the B test paper does not have a purple-red strip, it indicates an incorrect operation process or failure.
- the above-mentioned detection test paper also has the advantages of simple detection operation, short time, high specificity and high sensitivity during detection.
- Fig. 1 is the schematic diagram of the new coronavirus neutralizing antibody detection test paper A test paper in the embodiment of the present invention 1;
- Example 2 is a schematic diagram of a novel coronavirus neutralizing antibody detection device in Example 1 of the present invention.
- FIG. 3 is a colorimetric card in Experimental Example 1 of the present invention.
- Goat anti-rabbit IgG polyclonal antibody was purchased from Hangzhou Zhengzhi Biotechnology Co., Ltd.
- mouse anti-human IgG monoclonal antibody was purchased from Hangzhou Zhengzhi Biotechnology Co., Ltd.
- angiotensin-converting enzyme 2 was purchased from Anyuan Pharmaceutical Technology (Shanghai) Co., Ltd. Catalog#hACE2-hFc
- the receptor binding domain RBD antigen (S-RBD) of the novel coronavirus S protein was purchased from Anyuan Pharmaceutical Technology (Shanghai) Co., Ltd. Catalog#SARS-CoV-2RBD
- This embodiment provides a new coronavirus neutralizing antibody detection test paper, including:
- FIG. 1 it includes a substrate 1 and a sample loading pad 2, a colloidal gold adsorption pad 3, an antibody-bearing film 4 and a water-absorbing pad 5 are overlapped and overlapped on the substrate 1 in sequence;
- a detection line T1 , a detection line T2 and a quality control line C are provided at intervals, the detection line T2 is close to the colloidal gold adsorption pad 3 , and the quality control line C is close to the water absorption pad 5 .
- the colloidal gold adsorption 3 is coated with the colloidal gold-labeled receptor binding domain RBD antigen of the new coronavirus S protein and the colloidal gold-labeled antibody unrelated to the new coronavirus, in this example, the selection of the antibody unrelated to the new coronavirus for rabbit IgG.
- the detection line T1 is coated with a secondary antibody of novel coronavirus antibody IgG, in this example, a mouse anti-human IgG monoclonal antibody.
- the detection line T2 is coated with angiotensin-converting enzyme 2.
- the quality control line C is coated with a secondary antibody that specifically binds to an antibody unrelated to colloidal gold-labeled 2019-nCoV.
- the secondary antibody is a goat anti-rabbit IgG polyclonal antibody.
- the distance between the detection line T2, the detection line T1 and the quality control line C is 4-6 mm, and in this embodiment, the distance is selected to be 5 mm.
- a protective film 6 is provided on both the sample loading pad 2 and the water absorbing pad 5 .
- the present embodiment provides a method for preparing the new coronavirus neutralizing antibody detection test paper in Example 1, and the preparation steps of the test paper are as follows:
- the antibody concentration is 0.5-0.6 mg/ml, and in this example, it is 0.5 mg/ml.
- the concentration of ACE-2 is 1.5-2.0mg/ml, in this example, it is 1.8mg/ml
- the goat anti-rabbit IgG for coating the quality control line is prepared with sodium chloride buffer with a mass percentage of 0.85%.
- the antibody concentration is 2.0-2.5 mg/ml, in this example, 2.2 mg/ml.
- the nitrocellulose membrane is dried at a constant temperature of 2°C to 30°C for use.
- the closed treatment soaking solution contains 0.1Mol buffer solution and 0.5% sugar by mass. 1% blocking protein by mass, and 0.05% preservative by mass, wherein the buffer is phosphate buffer, the sugar is sucrose, the preservative is thimerosal, and the blocking protein is bovine serum albumin .
- Drying of the sticker Tear off the white paper in the middle of the cutting line on the double-sided tape of the plastic board, and use tweezers to place the sealed antibody-carrying film on the blank position in the center of the plastic board, and the right side of the plastic board is flush with the right side of the film , to avoid errors in the production process, to ensure that the color development position is relatively accurate, when pasting the board, all the top quality control lines are pasted at one end.
- the temperature in the control room is 18 ⁇ 28°C, the relative humidity is less than or equal to 40%, and the air in the drying room can be circulated and the dehumidifier wind will not blow directly on the film surface. Drying time ⁇ 4 hours, after use.
- colloidal gold complex solution add the actual production volume of purified water to the dosing tank; weigh trehalose, bovine serum albumin, trisodium citrate, polyethylene glycol and NaN 3 with an electronic analytical balance, and directly add Stir in the liquid preparation tank, stir until completely dissolved, add purified water to the required volume, stir well, and stir for more than 30 minutes, the obtained colloidal gold complex solution contains 5% by mass of trehalose, 2% by mass of bovine serum albumin, 0.5% by mass of trisodium citrate, 0.05% by mass of polyethylene glycol, and 0.05% by mass of NaN 3 .
- the final concentration of the rabbit IgG antibody was 4ug/ml
- the rabbit IgG antibody was added to the colloidal gold, stirred on a magnetic stirrer for 30 minutes, and the stabilizer polyethylene glycol with a volume percentage of 0.5 ⁇ was added, and after stirring for 30 minutes Centrifuge, collect the precipitate, reconstitute with 3% colloidal gold reconstituted solution by volume, stir on a magnetic stirrer until uniformly mixed to obtain a 3% vol % colloidal gold-rabbit IgG antibody conjugate reconstituted solution for use .
- the colloidal gold is cast, because the casted colloidal gold can be freely cut to the width, so that it is convenient to adjust the depth and color of the product.
- This embodiment provides a novel coronavirus neutralizing antibody detection device, as shown in FIG. 2 , including a housing 7, and two side-by-side devices inside the housing 7 have the novel coronavirus neutralizing antibody detection test strips of Example 1 .
- a sample hole 8 is set at the corresponding sample pad, and an observation port 9 is set at the detection line T2, the detection line T1 and the quality control line C. .
- This embodiment provides a novel coronavirus neutralizing antibody detection kit, including the novel coronavirus neutralizing antibody detection test paper of Example 1 or Example 2, or the novel coronavirus neutralizing antibody detection device in Example 3.
- the present embodiment provides a non-disease diagnosis and detection method for a novel coronavirus neutralizing antibody, comprising the following steps:
- test strip (do not open the foil bag) to room temperature.
- the test paper is recorded as the B test paper, and then 20ul of the sample is drawn into the A hole, and then 2 drops of the diluent are added dropwise to the A hole, and the test paper is recorded as the A test paper.
- test strips and droppers used should be disposed of as biomedical waste.
- test strip should be removed from the original packaging as soon as possible within 1 hour, especially if the room temperature is higher than 30°C or in a high humidity environment. At room temperature, process within 1 hour of sample collection. If the processed samples cannot be tested in time, the processed samples should be refrigerated at 2-8°C and tested within 12 hours after processing. Freezing and thawing of samples is strictly prohibited.
- test paper A Color development of test paper A: a purple-red band appeared at the quality control line C and the detection line T2, and there was no purple-red band at the detection line T1. The results showed that the new coronavirus neutralizing antibody could not be detected in the specimen.
- the color development of test paper B was consistent with the color development of test paper A, and it was negative.
- the appearance of the purple-red band at the quality control line is used as a standard for the internal control of the kit to determine whether there is enough sample, whether the chromatography process is normal, whether the correct procedure is used, and the correct test results are obtained.
- G1 ⁇ G14 gradually increase the color, G1 is no color.
- the new coronavirus neutralizing antibody detection test strip of the present invention can detect the concentration of the new coronavirus neutralizing antibody, and can detect the concentration of the neutralizing antibody as low as 0.625 ⁇ g/mL, with high specificity and high sensitivity during detection.
- the above-mentioned detection test paper also has the advantages of simple detection operation and short time.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Food Science & Technology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Tropical Medicine & Parasitology (AREA)
- Peptides Or Proteins (AREA)
Abstract
本发明提供了一种新型冠状病毒中和抗体检测试纸、试剂盒以及检测方法和用途，包括：基片以及在基片上依次重叠搭接有上样垫、胶体金吸附垫、抗体承载膜和吸水垫；抗体承载膜上设置有相间隔的检测线T1、检测线T2和质控线C，检测线T2靠近胶体金吸附垫，质控线C靠近吸水垫；胶体金吸附垫上包被胶体金标记的新型冠状病毒S-RBD抗原和胶体金标记的与新冠病毒无关的抗体，检测线T1包被新冠病毒抗体IgG的二抗；检测线T2包被血管紧张素转化酶2；质控线C包被与胶体金标记的新冠病毒无关的抗体特异性结合的二抗；上述检测试纸可以检测新型冠状病毒中和抗体，操作简单，时间短，且检测时特异性高、灵敏度高。
Description
交叉引用
本申请要求在2021年01月28日提交中国专利局、申请号为2021101198503、发明名称为“一种新型冠状病毒中和抗体检测试纸”的中国专利申请的优先权，其全部内容通过引用结合在本申请中。
本发明涉及生物医学检测领域，具体涉及一种新型冠状病毒中和抗体检测试纸、试剂盒以及检测方法和用途。
随着全球抗击新型冠状病毒疫情进入持久阶段,除了尚处于临床试验阶段的新冠疫苗，能有效阻断新冠病毒的中和抗体也被陆续发现，作为一种候选疗法，给学界带来了新的希望。
抗体是人体内B淋巴细胞受到抗原刺激而产生的一种具有免疫效应的蛋白质，主要存在于血液和组织中。抗体具有Y字形结构，这可以帮助它们精确地捕捉抗原。微生物入侵人体后，刺激机体产生多种抗体，其中只有部分抗体能产生对微生物的识别，并在其入侵细胞前将其捕获，保护人体不受感染。这个过程被称为中和作用，发挥作用的抗体就是中和抗体。在抗击新冠病毒过程中，中和抗体疗法就是人为地补给抗体来支援免疫系统，以免受新冠病毒感染。
目前来说，中和抗体主要有三种。第一种是血清疗法，即人感染新冠病毒后，会产生一种IgG抗体，这是一种中和抗体，提取新冠肺炎康复者血清用于治疗其他重症肺炎患者就是这个道理。这种方法应用的最快，但存在一定风险。第二种是单克隆抗体，这是一种经过人为筛选和制备的抗体，成分单一，特异性强，又被称为“生物导弹”。单克隆抗体可以精确识别新冠病毒的某个抗原部位，产生高效的抗病毒效应。最后一种是基因工程抗体，是对抗体的氨基酸序列进行修饰，疗效更强。中和抗体和疫苗的区别是，疫苗旨在训练人体免疫系统掌握消灭新冠病毒的方法，等到病毒入侵时有效地清除它们，重在预防。而中和抗体药物主要是精准高效地杀伤新冠病毒，起效快，具有可观的治疗作用。
中和抗体的检测可决定是否能够更安全地重返工作岗位或参加更多的社交活动，现阶段确认康复患者或无症状感染者有无再度感染风险，后期随着疫苗的研制成功并广泛应用，可作为疫苗效果的评价指标。现有针对新冠中和抗体的检测方法主要包括酶联免疫、化学发光等检测手段，该两种方法已有对应的试剂盒上市。但是，上述方法的检测操作较为复杂且耗时较长，且检测时特异性低、灵敏度差，且无法判断中和抗体的浓度水平。
发明内容
因此，本发明要解决的技术问题在于现有的新型冠状病毒中和抗体的检测操作较为复杂且耗时较长，且检测时特异性低、灵敏度差，无法判断中和抗体的浓度水平，从而提供一种新型冠状病毒中和抗体检测试纸、试剂盒以及检测方法和用途。
为此，本发明提供了如下的技术方案：
一种新型冠状病毒中和抗体检测试纸，包括：基片以及在所述基片上依次重叠搭接有上样垫、胶体金吸附垫、抗体承载膜和吸水垫；所述抗体承载膜上设置有相间隔的检测线T1、检测线T2和质控线C，所述检测线T2靠近所述胶体金吸附垫，所述质控线C靠近所述吸水垫；
所述胶体金吸附垫上包被胶体金标记的新型冠状病毒S蛋白的受体结合结构域RBD抗原和胶体金标记的与新冠病毒无关的抗体；
所述检测线T1包被新型冠状病毒抗体IgG的二抗；
所述检测线T2包被血管紧张素转化酶2；
所述质控线C包被与胶体金标记的新冠病毒无关的抗体特异性结合的二抗。
可选的，所述新型冠状病毒抗体IgG的二抗为鼠抗人IgG单克隆抗体；或
所述胶体金标记的与新冠病毒无关的抗体为兔IgG抗体；或
所述胶体金标记的新冠病毒无关的抗体特异性结合的二抗为羊抗兔IgG多抗。
本发明提供了一种所述的新型冠状病毒中和抗体检测试纸的制备方法，包括如下步骤：
将上样垫、胶体金吸附垫、抗体承载膜和吸水垫依次搭接在基片上；
将胶体金标记的新型冠状病毒S蛋白的受体结合结构域RBD抗原和胶体金标记的与新冠病毒无关的抗体包被在所述胶体金吸附垫上；
将新型冠状病毒抗体IgG的二抗、血管紧张素转化酶2和与胶体金标记的新冠病毒无关的抗体特异性结合的二抗分别包被在抗体承载膜上的检 测线T1、检测线T2和质控线C上。
可选的，所述新型冠状病毒抗体IgG的二抗为鼠抗人IgG单克隆抗体；或
所述胶体金标记的与新冠病毒无关的抗体为兔IgG抗体；或
所述胶体金标记的新冠病毒无关的抗体特异性结合的二抗为羊抗兔IgG多抗。
可选的，所述羊抗兔IgG多抗包被浓度：2.0～2.5mg/ml；或
所述鼠抗人IgG单克隆抗体包被浓度：0.5～0.6mg/ml；或
血管紧张素转化酶2包被浓度：1.5～2.0mg/ml；或
新型冠状病毒S蛋白的受体结合结构域RBD抗原的胶体金标记浓度：4～5μg/ml；或
兔IgG的胶体金标记浓度：4～5μg/ml。
本发明提供了一种新型冠状病毒中和抗体检测装置，包括壳体，和其内部装置的所述的新型冠状病毒中和抗体检测试纸或所述的制备方法制备得到的新型冠状病毒中和抗体检测试纸；
所述壳体上沿着所述新型冠状病毒中和抗体检测试纸层析方向，在对应样品垫处设置样品孔，在检测线T2、检测线T1和质控线C处设置观察口。
本发明提供了一种新型冠状病毒中和抗体检测试剂盒，包括所述的新型冠状病毒中和抗体检测试纸、所述的制备方法制备得到的新型冠状病毒中和抗体检测试纸或所述的新型冠状病毒中和抗体检测装置。
本发明所述的新型冠状病毒中和抗体检测试纸、所述的制备方法制备 得到的新型冠状病毒中和抗体检测试纸或所述的新型冠状病毒中和抗体检测装置在制备检测新型冠状病毒中和抗体的产品中的用途。
本发明提供了一种新型冠状病毒中和抗体的非疾病诊断的检测方法，利用所述的新型冠状病毒中和抗体检测试纸、所述的制备方法制备得到的新型冠状病毒中和抗体检测试纸或所述的新型冠状病毒中和抗体检测装置。
可选的，将样本加到检测试纸的上样垫上，然后加稀释液于上样垫上，所述检测试纸记为A试纸；同时加稀释液于另一检测试纸上，做阴性对照，所述检测试纸记为B试纸；于15分钟后观察A试纸和B试纸，20分钟后结果无效；
可选的，当A试纸质控线C和检测线T2处出现紫红色条带，检测线T1未出现紫红色条带，A试纸显色结果与B试纸显色结果一致，检测结果为阴性；
当A试纸在检测线T1处出现浅紫红色条带，检测线T2处出现紫红色条带，检测线T2显色比检测线T1显色深，A试纸检测线T2显色比B试纸检测线T2显色浅，检测结果表明样本中含有新型冠状病毒中和抗体低滴度；
当A试纸在检测线T1和检测线T2处均出现浅紫红色条带，检测线T1和检测线T2显色深度相当，A试纸检测线T2显色比B试纸检测线T2显色浅，检测结果表明样本中含有新型冠状病毒中和抗体中滴度；
当A试纸在T1检测线处出现紫红色条带，在T2检测线处未出现紫红色条带，检测结果表明样本中含有新型冠状病毒中和抗体高滴度；
若A试纸和B试纸的质控线C未出现紫红色条带，表明不正确操作过程或失效。
本发明技术方案，具有如下优点：
1.本发明提供的新型冠状病毒中和抗体检测试纸，基片以及在所述基片上依次重叠搭接有上样垫、胶体金吸附垫、抗体承载膜和吸水垫；所述抗体承载膜上设置有相间隔的检测线T1、检测线T2和质控线C，所述检测线T2靠近所述胶体金吸附垫，所述质控线C靠近所述吸水垫；所述胶体金吸附垫上包被胶体金标记的新型冠状病毒S蛋白的受体结合结构域RBD抗原和胶体金标记的与新冠病毒无关的抗体；所述检测线T1包被新型冠状病毒抗体IgG的二抗；所述检测线T2包被血管紧张素转化酶2；所述质控线C包被与胶体金标记的新冠病毒无关的抗体特异性结合的二抗；上述检测试纸中，在胶体金垫上预包被胶体金标记新型冠状病毒S蛋白的受体结合结构域(S-RBD)抗原，在硝酸纤维膜检测线T1、T2和质控线处分别包被鼠抗人IgG单克隆抗体、血管紧张素转化酶2(ACE-2)以及羊抗兔IgG抗体，T1检测线应用捕获法，T2检测线应用竞争抑制法的原理，可以定性检测样本中中和抗体，同时可以检测样本中的中和抗体浓度水平的高低，原理如下：
检测阳性样本时，样本中新型冠状病毒中和抗体与胶体金标记的新型冠状病毒S蛋白的受体结合结构域(S-RBD)抗原结合形成复合物，由于层析作用复合物沿纸条向前移动：
当A试纸质控线C和检测线T2处出现紫红色条带，检测线T1未出现紫红色条带，A试纸显色结果与B试纸显色结果一致，检测结果为阴性；
当A试纸在检测线T1处出现浅紫红色条带，检测线T2处出现紫红色条带，检测线T2显色比检测线T1显色深，A试纸检测线T2显色比B试纸检测线T2显色浅，检测结果表明样本中含有新型冠状病毒中和抗体低滴度；
当A试纸在检测线T1和检测线T2处均出现浅紫红色条带，检测线T1和检测线T2显色深度相当，A试纸检测线T2显色比B试纸检测线T2显色浅，检测结果表明样本中含有新型冠状病毒中和抗体中滴度；
当A试纸在T1检测线处出现紫红色条带，在T2检测线处未出现紫红色条带，检测结果表明样本中含有新型冠状病毒中和抗体高滴度；
若A试纸和B试纸的质控线C未出现紫红色条带，表明不正确操作过程或失效。
进一步的，上述检测试纸还具有检测操作简单，时间短，且检测时特异性高、灵敏度高的优势。
为了更清楚地说明本发明具体实施方式或现有技术中的技术方案，下面将对具体实施方式或现有技术描述中所需要使用的附图作简单地介绍，显而易见地，下面描述中的附图是本发明的一些实施方式，对于本领域普通技术人员来讲，在不付出创造性劳动的前提下，还可以根据这些附图获得其他的附图。
图1是本发明实施例1中的新型冠状病毒中和抗体检测试纸A试纸的示意图；
图2是本发明实施例1中新型冠状病毒中和抗体检测装置的示意图；
图3是本发明实验例1中的比色卡。
附图标记：
1-基片，2-上样垫，3-胶体金吸附垫，4-抗体承载膜，5-吸水垫，6-保护膜，7-壳体，8-样品孔，9-观察口，T1-检测线T1，T2-检测线T2，C-质控线C。
提供下述实施例是为了更好地进一步理解本发明，并不局限于所述最佳实施方式，不对本发明的内容和保护范围构成限制，任何人在本发明的启示下或是将本发明与其他现有技术的特征进行组合而得出的任何与本发明相同或相近似的产品，均落在本发明的保护范围之内。
实施例中未注明具体实验步骤或条件者，按照本领域内的文献所描述的常规实验步骤的操作或条件即可进行。所用试剂或仪器未注明生产厂商者，均为可以通过市购获得的常规试剂产品。
羊抗兔IgG多抗购自杭州正知生物技术有限公司，鼠抗人IgG单克隆抗体购自杭州正知生物技术有限公司，血管紧张素转化酶2购自安源医药科技(上海)有限公司Catalog#hACE2-hFc，新型冠状病毒S蛋白的受体结合结构域RBD抗原(S-RBD)购自安源医药科技(上海)有限公司Catalog#SARS-CoV-2RBD
实施例1新型冠状病毒中和抗体检测试纸
本实施例提供了一种新型冠状病毒中和抗体检测试纸，包括：
如图1所示，包括基片1以及在所述基片1上依次重叠搭接有上样垫2、胶体金吸附垫3、抗体承载膜4和吸水垫5；所述抗体承载膜4上设置有相 间隔的检测线T1、检测线T2和质控线C，所述检测线T2靠近所述胶体金吸附垫3，所述质控线C靠近所述吸水垫5。所述胶体金吸附3上包被胶体金标记的新型冠状病毒S蛋白的受体结合结构域RBD抗原和胶体金标记的与新冠病毒无关的抗体，在本实施例中与新冠病毒无关的抗体选择为兔IgG。所述检测线T1包被新型冠状病毒抗体IgG的二抗，在本实施例中鼠抗人IgG单克隆抗体。所述检测线T2包被血管紧张素转化酶2。所述质控线C包被与胶体金标记的新冠病毒无关的抗体特异性结合的二抗，在本实施例中二抗选择羊抗兔IgG多抗。在本实施例中，沿着层析方向，检测线T2、检测线T1和质控线C之间的间距为4-6mm，在本实施例中选择间距为5mm。
进一步的，上样垫2和吸水垫5上均设置有保护膜6。
实施例2
本实施例提供了一种制备实施例1中的新型冠状病毒中和抗体检测试纸的方法，试纸的制备步骤如下：
1.抗体承载膜的制备：
(1)选择3μm～10μm孔径的硝酸纤维素膜，根据需要将膜分切成宽度为2.0cm,长度为30.5cm的规格，备用。
(2)用0.1M、pH8.0的Tris-HCL缓冲液配制供检测线包被使用的鼠抗人IgG单克隆抗体，抗体浓度为0.5～0.6mg/ml，本实施例中为0.5mg/ml，ACE-2浓度为1.5～2.0mg/ml，本实施例中为1.8mg/ml，用质量百分含量0.85％的氯化钠缓冲液配制供质控线包被使用的羊抗兔IgG多抗，使抗体浓度为2.0～2.5mg/ml，本实施例中为2.2mg/ml。
(3)选择硝酸纤维素膜的抗体包被面并作标记，将需包被的检测线和质控线的溶液平行均匀的包被在膜片上，且检测线与质控线的间距控制在距离C—T1：4.0mm，T1—T2：4.0mm，硝酸纤维素膜在2℃～30℃的恒温条件下干燥备用。
(4)配制封闭处理浸泡液，向配液罐加入实际生产量的纯化水；分别称量缓冲液、糖份、封闭蛋白和防腐剂，将以上组分直接加入到配液罐中搅拌，直至完全溶解，加纯化水定容至所需体积，充分搅拌均匀，搅拌时间不少于10分钟，备用；其中配制的封闭处理浸泡液中含有0.1Mol缓冲液、质量百分含量为0.5％的糖份、质量百分含量为1％的封闭蛋白、质量百分含量为0.05％的防腐剂，其中，缓冲液为磷酸盐缓冲液，糖份为蔗糖，防腐剂为硫柳汞，封闭蛋白为牛血清蛋白。
(5)将包被了检测线和质控线的膜放于处理槽中，加入配好的上述(4)的封闭处理浸泡液，确保每条膜完全浸没在上述(4)的封闭处理浸泡液中30分钟，并保证膜不移动、不重叠，30分钟后将膜从处理槽中取出，将上述(4)的封闭处理浸泡液倒掉；用镊子将膜放在纱布上晾稍干，得到抗体承载膜。
(6)贴板干燥：撕去胶板双面胶上切割线中间的白纸，用镊子将封闭处理后的抗体承载膜正好放在胶板中央空白位置，且胶板右边与膜右边平齐，避免在生产过程中的误差，确保显色位置相对准确，贴板时全部顶质控线一头贴，膜贴在胶板上后，隔着双面胶纸抹平膜面，避免有气泡，控制室内的温度18～28℃、相对湿度≤40％，并保证干燥间空气能循环流通且除湿机风不会直接吹到膜面上。干燥时间≥4小时，后备用。
2.胶体金吸附垫的制备
(1)胶体金复溶液的配制：向配液罐加入实际生产量的纯化水；用电子分析天平称量海藻糖、牛血清白蛋白、柠檬酸三钠、聚乙二醇和NaN
3，直接加入到配液罐中搅拌，搅拌直至完全溶解，加纯化水定容至所需体积，充分搅拌均匀，搅拌时间大于30分钟，得到的胶体金复溶液中含有质量百分含量5％的海藻糖、质量百分含量2％的牛血清白蛋白、质量百分含量0.5％的柠檬酸三钠、质量百分含量0.05％的聚乙二醇、质量百分含量0.05％的NaN
3。
(2)用量筒量取需要标记量的胶体金，按pH7.0-7.3进行调节，即按体积百分含量为0.50％加入0.2mol/L的碳酸钾溶液，于磁力搅拌器上搅拌15分钟后，取新型冠状病毒(S-RBD)抗原，用双蒸水将新型冠状病毒(S-RBD)抗原进行稀释，并按4～5μg/ml标记胶体金(即向新型冠状病毒(S-RBD)抗原稀释液中加入胶体金后，新型冠状病毒(S-RBD)抗原的终浓度4-5ug/ml，在本实施例中选择4μg/ml)，将新型冠状病毒(S-RBD)抗原加入胶体金中，于磁力搅拌器上搅拌30分钟，加入体积百分含量0.5‰的稳定剂聚乙二醇，搅拌30分钟后离心，收集沉淀，用胶体金复溶液按体积百分含量3％复溶，于磁力搅拌器上搅拌至混合均匀，得到体积百分含量3％的胶体金－新型冠状病毒(S-RBD)抗原结合物复溶液，备用。
(3)用量筒量取需要标记量的胶体金，按pH7.0-7.3进行调节，即按体积百分含量为0.50％加入0.2mol/L的碳酸钾溶液，于磁力搅拌器上搅拌15分钟后，取兔IgG抗体，用双蒸水将兔IgG抗体进行稀释，并按4-5ug/ml标记胶体金(在本实施例中选择4ug/ml，即向兔IgG抗体稀释液中加入胶 体金后，兔IgG抗体的终浓度4ug/ml)，将兔IgG抗体加入胶体金中，于磁力搅拌器上搅拌30分钟，加入体积百分含量0.5‰的稳定剂聚乙二醇，搅拌30分钟后离心，收集沉淀，用胶体金复溶液按体积百分含量3％复溶，于磁力搅拌器上搅拌至混合均匀，得到体积百分含量3％的胶体金－兔IgG抗体结合物复溶液，备用。
(4)取上述(2)和(3)中体积百分含量3％的胶体金－新型冠状病毒(S-RBD)抗原结合物复溶液和胶体金－兔IgG抗体结合物复溶液，用胶体金复溶液按体积百分含量50％进行复溶，于磁力搅拌器上混合均匀，按照50μl/cm
2浇制在准备好的胶体金吸附垫上，置于干燥室晾干≥4个小时，干燥室控制温度18-28℃，相对湿度≤40％，保证空气畅通且气流不能直接吹于胶体金吸附垫上，将干燥好的胶体金吸附垫放入到装有干燥剂的铝箔袋中，密封保存，做好标记胶体金吸附垫，备用。
注：胶体金为浇制，是因为浇制的胶体金可以自由的裁切宽度，从而方便调节产品的深浅显色。
3.组装及裁切：
(1)取已粘贴抗体承载膜的透明基片半成品，将试纸条胶体金吸附垫按0.5cm宽度裁切成0.5cm×30cm的条状后粘贴在靠近检测线一侧的透明基片上，并保持与抗体承载膜呈搭接约1mm，将试纸条吸水垫复合在靠近质控线一侧的透明基片上并与抗体承载膜搭接约1mm，将试纸条上样垫复合在试纸条胶体金吸附垫远离抗体承载膜的一端并与其搭接约1mm，做好标记，备用；
(2)将已组装备用的基片，切割成条状试纸备用。
实施例3
本实施例提供了一种新型冠状病毒中和抗体检测装置，如图2所示，包括壳体7，所述壳体7内部并排装置有两个实施例1的新型冠状病毒中和抗体检测试纸。所述壳体7上沿着所述新型冠状病毒中和抗体检测试纸层析方向，在对应样品垫处设置样品孔8，在检测线T2、检测线T1和质控线C处设置观察口9。
实施例4
本实施例提供了一种新型冠状病毒中和抗体检测试剂盒，包括实施例1或实施例2的新型冠状病毒中和抗体检测试纸，或实施例3中的新型冠状病毒中和抗体检测装置。
实施例5
本实施例提供了一种新型冠状病毒中和抗体的非疾病诊断检测方法，包括如下步骤：
将试纸(不要打开铝箔袋)恢复至室温。
打开铝箔包装袋，取出检测装置，并平置于台面上。
垂直滴加2滴稀释液(在本实施例中稀释液为含0.01M PBS，络蛋白盐0.3％(w/v)，防腐剂0.05％(w/v)，pH7.0)于B孔中，做阴性对照，所述试纸记为B试纸，然后吸取20ul样本加入A孔，再滴加2滴稀释液于A孔中，所述试纸记为A试纸。
15分钟后观察并记录结果，20分钟后结果无效。
试验结束后，使用的检测试纸、滴管应作为生物医学废弃物处理。
注意:1小时内尽快从原包装应使用中取出试纸，特别是在室温高于30℃或高湿环境下。在常温下，样品采集后1小时内处理。处理后的样品如不能及时检测，应将处理后的样品冷藏2-8℃，并在处理后12小时内进行检测。严禁对样品进行冻融处理。
2.结果判定：
2.1阴性：
A试纸显色：质控线C和检测线T2处出现紫红色条带，检测线T1未出现紫红色条带，结果表明：标本中未能检出新型冠状病毒中和抗体。B试纸显色结果与A试纸结果显色一致，为阴性。
2.2阳性：
(1)A试纸在检测线T1处出现一条浅紫红色条带，检测线T2处出现一条紫红色条带，检测线T2显色比检测线T1显色深，但A试纸检测线T2显色比B试纸检测线T2显色浅。结果表明：样本中含有新型冠状病毒中和抗体低滴度。
(2)A试纸在检测线T1和检测线T2处均出现一条浅紫红色条带，检测线T1和T2显色深度相当，A试纸检测线T2显色比B试纸检测线T2显色浅。结果表明：样本中含有新型冠状病毒中和抗体中滴度。
(3)A试纸在检测线T1处出现一条紫红色条带，在检测线T2处未出现紫红色条带。结果表明：标本中含有新型冠状病毒中和抗体高滴度。
失效：质控线C未出现紫红色条带，表明不正确操作过程或试剂盒失效。在此情况下应再次仔细阅读说明书，并用新的试纸卡重新检测。
质控线处出现紫红色条带是作为试剂盒内在控制的标准，以确定是否 有足够标本、层析过程是否正常、是否使用了正确的操作步骤和得到正确的测试结果。
实验例1
选取市售的新冠病毒的重组中和抗体(购自安源医药科技(上海)有限公司Catalog#REGN-10933)配制成具有如下表1中的浓度的溶液作为待测样品，按照实施例5的新型冠状病毒中和抗体的非疾病诊断检测方法进行检测，显色结果与图3的比色卡进行比对，检测结果见下表1。
表1、检测结果
注：G1～G14显色逐渐增强，G1为不显色。
由以上结果可知，本发明的新型冠状病毒中和抗体检测试纸能够检测新冠病毒中和抗体的浓度的高低，可以检测中和抗体的浓度低至0.625μg/mL，检测时特异性高、灵敏度高，上述检测试纸还具有检测操作简单，时间短。
显然，上述实施例仅仅是为清楚地说明所作的举例，而并非对实施方式的限定。对于所属领域的普通技术人员来说，在上述说明的基础上还可以做出其它不同形式的变化或变动。这里无需也无法对所有的实施方式予以穷举。而由此所引伸出的显而易见的变化或变动仍处于本发明创造的保护范围之中。
Claims (10)
- 一种新型冠状病毒中和抗体检测试纸，其特征在于，包括：基片以及在所述基片上依次重叠搭接有上样垫、胶体金吸附垫、抗体承载膜和吸水垫；所述抗体承载膜上设置有相间隔的检测线T1、检测线T2和质控线C，所述检测线T2靠近所述胶体金吸附垫，所述质控线C靠近所述吸水垫；所述胶体金吸附垫上包被胶体金标记的新型冠状病毒S蛋白的受体结合结构域RBD抗原和胶体金标记的与新冠病毒无关的抗体；所述检测线T1包被新型冠状病毒抗体IgG的二抗；所述检测线T2包被血管紧张素转化酶2；所述质控线C包被与胶体金标记的新冠病毒无关的抗体特异性结合的二抗。
- 根据权利要求1所述的新型冠状病毒中和抗体检测试纸，其特征在于，所述新型冠状病毒抗体IgG的二抗为鼠抗人IgG单克隆抗体；或所述胶体金标记的与新冠病毒无关的抗体为兔IgG抗体；或所述胶体金标记的与新冠病毒无关的抗体特异性结合的二抗为羊抗兔IgG多抗。
- 一种如权利要求1-2任一项所述的新型冠状病毒中和抗体检测试纸的制备方法，其特征在于，包括如下步骤：将上样垫、胶体金吸附垫、抗体承载膜和吸水垫依次搭接在基片上；将胶体金标记的新型冠状病毒S蛋白的受体结合结构域RBD抗原和胶体金标记的与新冠病毒无关的抗体包被在所述胶体金吸附垫上；将新型冠状病毒抗体IgG的二抗、血管紧张素转化酶2和与胶体金标记的新冠病毒无关的抗体特异性结合的二抗分别包被在抗体承载膜上的检测线T1、检测线T2和质控线C上。
- 根据权利要求3所述的制备方法，其特征在于，所述新型冠状病毒抗体IgG的二抗为鼠抗人IgG单克隆抗体；或所述胶体金标记的与新冠病毒无关的抗体为兔IgG抗体；或所述胶体金标记的与新冠病毒无关的抗体特异性结合的二抗为羊抗兔IgG多抗。
- 根据权利要求4所述的制备方法，其特征在于，所述羊抗兔IgG多抗包被浓度：2.0～2.5mg/ml；或所述鼠抗人IgG单克隆抗体包被浓度：0.5～0.6mg/ml；或血管紧张素转化酶2包被浓度：1.5～2.0mg/ml；或新型冠状病毒S蛋白的受体结合结构域RBD抗原的胶体金标记浓度：4～5μg/ml；或兔IgG的胶体金标记浓度：4～5μg/ml。
- 一种新型冠状病毒中和抗体检测装置，其特征在于，包括壳体，和其内部装置的权利要求1-2任一项所述的新型冠状病毒中和抗体检测试纸或权利要求3-5任一项所述的制备方法制备得到的新型冠状病毒中和抗体检测试纸；所述壳体上沿着所述新型冠状病毒中和抗体检测试纸层析方向，在对应样品垫处设置样品孔，在检测线T2、检测线T1和质控线C处设置观察口。
- 一种新型冠状病毒中和抗体检测试剂盒，其特征在于，包括权利要求1-2任一项所述的新型冠状病毒中和抗体检测试纸、权利要求3-5任一项所述的制备方法制备得到的新型冠状病毒中和抗体检测试纸或权利要求6所述的新型冠状病毒中和抗体检测装置。
- 权利要求1-2任一项所述的新型冠状病毒中和抗体检测试纸、权利要求3-5任一项所述的制备方法制备得到的新型冠状病毒中和抗体检测试纸或权利要求6所述的新型冠状病毒中和抗体检测装置在制备检测新型冠状病毒中和抗体的产品中的用途。
- 一种新型冠状病毒中和抗体的非疾病诊断的检测方法，其特征在于，利用权利要求1-2任一项所述的新型冠状病毒中和抗体检测试纸、权利要求3-5任一项所述的制备方法制备得到的新型冠状病毒中和抗体检测试纸或权利要求6所述的新型冠状病毒中和抗体检测装置。
- 根据权利要求9所述的检测方法，其特征在于，将样本加到检测试纸的上样垫上，然后加稀释液于上样垫上，所述检测试纸记为A试纸；同时加稀释液于另一检测试纸上，做阴性对照，所述检测试纸记为B试纸；于15分钟后观察A试纸和B试纸，20分钟后结果无效；可选的，当A试纸质控线C和检测线T2处出现紫红色条带，检测线T1未出现紫红色条带，A试纸显色结果与B试纸显色结果一致，检测结果为阴性；当A试纸在检测线T1处出现浅紫红色条带，检测线T2处出现紫红色条带，检测线T2显色比检测线T1显色深，A试纸检测线T2显色比B试纸检测线T2显色浅，检测结果表明样本中含有新型冠状病毒中和抗体低滴 度；当A试纸在检测线T1和检测线T2处均出现浅紫红色条带，检测线T1和检测线T2显色深度相当，A试纸检测线T2显色比B试纸检测线T2显色浅，检测结果表明样本中含有新型冠状病毒中和抗体中滴度；当A试纸在T1检测线处出现紫红色条带，在T2检测线处未出现紫红色条带，检测结果表明样本中含有新型冠状病毒中和抗体高滴度；若A试纸和B试纸的质控线C未出现紫红色条带，表明不正确操作过程或失效。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110119850.3A CN112798797A (zh) | 2021-01-28 | 2021-01-28 | 一种新型冠状病毒中和抗体检测试纸 |
| CN202110119850.3 | 2021-01-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2022160377A1 true WO2022160377A1 (zh) | 2022-08-04 |
Family
ID=75812568
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/CN2021/075736 WO2022160377A1 (zh) | 2021-01-28 | 2021-02-07 | 一种新型冠状病毒中和抗体检测试纸 |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN112798797A (zh) |
| WO (1) | WO2022160377A1 (zh) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113295865B (zh) * | 2020-06-05 | 2022-09-06 | 南京金斯瑞生物科技有限公司 | 检测SARS-CoV-2病毒中和抗体的免疫层析装置及其应用 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111337669A (zh) * | 2020-03-03 | 2020-06-26 | 南通大学 | 一种快速检测新型冠状病毒检测试纸及检测方法 |
| CN211697830U (zh) * | 2019-09-04 | 2020-10-16 | 南通伊仕生物技术股份有限公司 | 一种促黄体生成素检测试纸及试纸卡 |
| CN111879951A (zh) * | 2020-08-17 | 2020-11-03 | 南通伊仕生物技术股份有限公司 | 新型冠状病毒IgA/IgG抗体联检免疫层析试纸条 |
| CN211905393U (zh) * | 2020-09-22 | 2020-11-10 | 正元盛邦(天津)生物科技有限公司 | 新型冠状病毒特异性抗体和中和抗体联合检测试纸及装置 |
-
2021
- 2021-01-28 CN CN202110119850.3A patent/CN112798797A/zh active Pending
- 2021-02-07 WO PCT/CN2021/075736 patent/WO2022160377A1/zh active Application Filing
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN211697830U (zh) * | 2019-09-04 | 2020-10-16 | 南通伊仕生物技术股份有限公司 | 一种促黄体生成素检测试纸及试纸卡 |
| CN111337669A (zh) * | 2020-03-03 | 2020-06-26 | 南通大学 | 一种快速检测新型冠状病毒检测试纸及检测方法 |
| CN111879951A (zh) * | 2020-08-17 | 2020-11-03 | 南通伊仕生物技术股份有限公司 | 新型冠状病毒IgA/IgG抗体联检免疫层析试纸条 |
| CN211905393U (zh) * | 2020-09-22 | 2020-11-10 | 正元盛邦(天津)生物科技有限公司 | 新型冠状病毒特异性抗体和中和抗体联合检测试纸及装置 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN112798797A (zh) | 2021-05-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111562369A (zh) | SARS-CoV-2中和抗体检测试剂盒 | |
| US9863945B2 (en) | Immunochromatography detection method | |
| ES2650395T3 (es) | Kits de diagnóstico y métodos de inmunoensayo para el diagnóstico y la diferenciación de virus de la fiebre porcina africana (ASFV) y virus de la fiebre porcina clásica (CSFV) | |
| CN111537748B (zh) | 一种检测人新型冠状病毒IgM抗体的试纸条、试剂盒及其制备方法 | |
| JP5431644B2 (ja) | 呼吸器感染症の検査方法 | |
| CN111351927A (zh) | 针对病原体抗原的抗体矩阵检测法（mega法）及多联检测卡 | |
| WO2021244629A1 (zh) | 检测SARS-CoV-2病毒中和抗体的免疫层析装置及其应用 | |
| WO2021159703A1 (zh) | 一种快速检测新型冠状病毒n蛋白的免疫层析试剂盒及其制备方法和应用 | |
| CN106814190A (zh) | Pct与crp联检试纸条及其制备方法 | |
| CN113702643A (zh) | 一种联合检测新型冠状病毒中和抗体及核衣壳蛋白抗体的装置 | |
| CN112748243A (zh) | 一种新型冠状病毒中和抗体检测试剂盒及其制备方法 | |
| CN107966561A (zh) | 一种检测hiv抗体的试纸条和试剂盒 | |
| CN113533721A (zh) | 甲型/乙型流感病毒抗原胶体金法检测试纸条及其制备方法 | |
| WO2022160377A1 (zh) | 一种新型冠状病毒中和抗体检测试纸 | |
| CN113567666A (zh) | 一种荧光微球标记的免疫层析法新型冠状病毒检测试纸条及其制备方法和应用 | |
| CN115060888A (zh) | 一种新型冠状病毒核衣壳蛋白抗原检测试纸的制备方法 | |
| CN213986500U (zh) | 新冠病毒IgM和IgG抗体胶体金法检测试剂盒 | |
| ES2402916T3 (es) | Método de ensayo con membrana y kit | |
| CN111879951A (zh) | 新型冠状病毒IgA/IgG抗体联检免疫层析试纸条 | |
| WO2023112859A1 (ja) | イムノクロマトグラフィー用テストストリップ、イムノクロマトグラフィーキット、及びそれらを用いた免疫測定方法、並びにサンプルの濾過方法 | |
| CN101706499A (zh) | Flag融合标签胶体金检测试纸条及其制备方法 | |
| CN106290863A (zh) | 一种人类丙肝病毒（hcv）唾液/尿液抗体胶体金检测试剂盒及其制备方法 | |
| JP2006084351A (ja) | 検体浮遊液組成物、キット及び検査方法 | |
| WO2023087550A1 (zh) | 一种检测新型冠状病毒抗原的试剂盒及检测方法 | |
| CN215066713U (zh) | 一种新型冠状病毒中和抗体检测试纸和检测装置 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21921976 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 21921976 Country of ref document: EP Kind code of ref document: A1 |